Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Hermann, M; Ruschitzka, F (2006). Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Internal Medicine Journal, 36(5):308-319.

Full text not available from this repository.

View at publisher

Abstract

The introduction of selective cyclooxygenase-2 inhibitors offered the promise of similar efficacy in pain control without the gastrointestinal effects associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs). By blocking prostacyclin formation but leaving platelet-derived thromboxane A2 generation unopposed, there is concern that the potential gastrointestinal benefit of cyclooxygenase-2-selective inhibitors may come at the cost of increased thrombotic risk. However, the differential effects of coxibs on blood pressure, endothelial function, oxidative stress, tissue factor expression, vascular smooth muscle proliferation and neointimal hyperplasia indicate a distinct heterogeneity among this class of drugs. Importantly, the observation of an excess cardiovascular risk with traditional NSAIDs in randomized clinical trials, meta-analysis and large-scale observational studies further highlights the need to scrutinize the entire class of anti-inflammatory drugs, including traditional NSAIDs, as rigorously as coxibs.

Citations

19 citations in Web of Science®
21 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology
DDC:610 Medicine & health
Language:English
Date:2006
Deposited On:11 Feb 2011 15:00
Last Modified:27 Nov 2013 22:16
Publisher:Wiley-Blackwell
ISSN:1444-0903
Publisher DOI:10.1111/j.1445-5994.2006.01056.x
PubMed ID:16650206

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page